TTP273
// TTP273
Overview
TTP273 is an oral, small molecule, glucagon-like peptide-1 (GLP-1) receptor agonist in development for the treatment of type 2 diabetes mellitus. TTP273 has been shown to reduce postprandial glucose excursions following oral glucose tolerance testing or mixed-meal tolerance testing in both preclinical and clinical studies.
GLP-1 is a naturally occurring hormone that serves as a ligand for the GLP-1 receptor (GLP-1R) and is associated with improved metabolic control, reduced inflammation, and cardioprotective and neuroprotective effects. GLP1-R agonists are established therapies for lowering glycosylated hemoglobin (HbA1c), providing cardiovascular benefit, and promoting weight reduction.
// HPP273
Clinical Studies
TTP273 was evaluated in two Phase 1 clinical studies and one 12-week Phase 2 clinical study. In a placebo-controlled Phase 1 study evaluating multiple doses and dosing regimens in healthy participants, TTP273 showed meaningful reductions in postprandial glucose following 14 days of dosing, as assessed by a mixed-meal tolerance test. In the 12-week Phase 2 study in participants with type 2 diabetes, TTP273 also showed a reduction in HbA1c. Across Phase 1 and Phase 2 clinical studies, TTP273 was generally well tolerated and was associated with lower incidences of gastrointestinal side effects, such as nausea and vomiting, compared with placebo.
Mechanism of Action
GLP-1 is a member of the incretin family of neuroendocrine peptide hormones that is secreted by intestinal L cells in response to food ingestion. GLP-1 exerts multiple metabolic effects that have been clinically validated by existing injectable peptide GLP-1R agonists in indications such as type 2 diabetes and obesity.
TTP273 is an oral, non-peptide, allosteric, standalone agonist of the GLP-1 receptor that activates the receptor independently of endogenous GLP-1. This mechanism enables oral receptor activation through non-peptide chemistry while producing metabolic effects consistent with GLP-1R agonism.